FR21C1038I2 - 5-fluoro-1h-pyrazolopyridines substituees et leur utilisation - Google Patents

5-fluoro-1h-pyrazolopyridines substituees et leur utilisation

Info

Publication number: FR21C1038I2
Authority: FR; France
Prior art keywords: pyrazolopyridines; fluoro; substituted
Prior art date: 2010-05-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR21C1038C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Adverio Pharma GmbH

Original Assignee

Adverio Pharma GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-05-26

Filing date

2021-08-30

Publication date

2022-09-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44119218&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR21C1038(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2021-08-30 Application filed by Adverio Pharma GmbH filed Critical Adverio Pharma GmbH

2021-10-15 Publication of FR21C1038I1 publication Critical patent/FR21C1038I1/fr

2022-09-02 Application granted granted Critical

2022-09-02 Publication of FR21C1038I2 publication Critical patent/FR21C1038I2/fr

Status Active legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/05—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

FR21C1038C 2010-05-26 2021-08-30 5-fluoro-1h-pyrazolopyridines substituees et leur utilisation Active FR21C1038I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE102010021637A DE102010021637A1 (de)	2010-05-26	2010-05-26	Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
PCT/EP2011/058431 WO2011147809A1 (fr)	2010-05-26	2011-05-24	5-fluoro-1h-pyrazolopyridines substituées et leur utilisation

Publications (2)

Publication Number	Publication Date
FR21C1038I1 FR21C1038I1 (fr)	2021-10-15
FR21C1038I2 true FR21C1038I2 (fr)	2022-09-02

Family

ID=44119218

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR21C1038C Active FR21C1038I2 (fr)	2010-05-26	2021-08-30	5-fluoro-1h-pyrazolopyridines substituees et leur utilisation

Country Status (46)

Country	Link
US (8)	US8420656B2 (fr)
EP (1)	EP2576547B1 (fr)
JP (1)	JP5896991B2 (fr)
KR (1)	KR101862420B1 (fr)
CN (1)	CN102939289B (fr)
AR (1)	AR081628A1 (fr)
AU (1)	AU2011257335B2 (fr)
BR (2)	BR112012030010A2 (fr)
CA (1)	CA2800697C (fr)
CL (1)	CL2012003226A1 (fr)
CO (1)	CO6640226A2 (fr)
CR (1)	CR20120596A (fr)
CU (1)	CU24086B1 (fr)
CY (2)	CY1117372T1 (fr)
DE (1)	DE102010021637A1 (fr)
DK (1)	DK2576547T3 (fr)
DO (1)	DOP2012000299A (fr)
EA (1)	EA023631B9 (fr)
EC (1)	ECSP12012310A (fr)
ES (1)	ES2567795T3 (fr)
FR (1)	FR21C1038I2 (fr)
GT (1)	GT201200313A (fr)
HR (1)	HRP20160370T1 (fr)
HU (2)	HUE026912T2 (fr)
IL (2)	IL223050A (fr)
JO (1)	JO3199B1 (fr)
LT (1)	LTC2576547I2 (fr)
LU (1)	LUC00221I2 (fr)
MA (1)	MA34248B1 (fr)
ME (1)	ME02393B (fr)
MX (1)	MX2012013324A (fr)
MY (1)	MY164356A (fr)
NL (1)	NL301146I2 (fr)
NO (1)	NO2021032I1 (fr)
NZ (1)	NZ603800A (fr)
PE (1)	PE20130402A1 (fr)
PH (1)	PH12012502320A1 (fr)
PL (1)	PL2576547T3 (fr)
RS (1)	RS54704B1 (fr)
SG (1)	SG185460A1 (fr)
SI (1)	SI2576547T1 (fr)
TN (1)	TN2012000549A1 (fr)
TW (1)	TWI516263B (fr)
UA (1)	UA109660C2 (fr)
UY (1)	UY33396A (fr)
WO (1)	WO2011147809A1 (fr)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102008063992A1 (de) *	2008-12-19	2010-09-02	Lerner, Zinoviy, Dipl.-Ing.	Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
DK3415515T3 (da)	2009-11-27	2020-03-16	Adverio Pharma Gmbh	Fremgangsmåde til fremstilling af methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamat
WO2011119518A1 (fr)	2010-03-25	2011-09-29	Merck Sharp & Dohme Corp.	Activateurs de guanylate cyclase solubles
DE102010021637A1 (de)	2010-05-26	2011-12-01	Bayer Schering Pharma Aktiengesellschaft	Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
CA2800541C (fr)	2010-05-27	2016-03-22	Merck Sharp & Dohme Corp.	Activateurs de guanylate cyclase soluble
PE20130779A1 (es)	2010-07-09	2013-06-21	Bayer Ip Gmbh	Pirimidinas y triazinas condensadas y su uso
US8895583B2 (en)	2010-10-28	2014-11-25	Merck Sharp & Dohme Corp.	Soluble guanylate cyclase activators
DE102010043380A1 (de)	2010-11-04	2012-05-10	Bayer Schering Pharma Aktiengesellschaft	Benzyl-substituierte Carbamate und ihre Verwendung
DE102010043379A1 (de)	2010-11-04	2012-05-10	Bayer Schering Pharma Aktiengesellschaft	Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
DE102011007272A1 (de)	2011-04-13	2012-10-18	Bayer Pharma Aktiengesellschaft	Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
WO2012143510A1 (fr)	2011-04-21	2012-10-26	Bayer Intellectual Property Gmbh	Pyrazolopyridines substituées par un fluoro-alkyle et leur utilisation
EP2594270A3 (fr) *	2011-11-18	2013-07-31	BIP Patents	Utilisation de stimulateurs de la sGC ou d'activateurs de la sGC, seuls et en combinaison avec des inhibiteurs de PDE5 pour le traitement de la sclérose systémique (Ssc)
PE20190180A1 (es) *	2011-11-25	2019-02-01	Adverio Pharma Gmbh	Procedimiento de preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas
CN102491974B (zh)	2011-12-12	2013-08-07	南京药石药物研发有限公司	1-（2-氟苄基）-1H-吡唑并[3，4-b]吡啶-3-甲脒盐酸盐的合成方法
DE102012200349A1 (de) *	2012-01-11	2013-07-11	Bayer Intellectual Property Gmbh	Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
DE102012200352A1 (de) *	2012-01-11	2013-07-11	Bayer Intellectual Property Gmbh	Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung
DE102012200360A1 (de)	2012-01-11	2013-07-11	Bayer Intellectual Property Gmbh	Substituierte Triazine und ihre Verwendung
WO2013131923A1 (fr)	2012-03-06	2013-09-12	Bayer Intellectual Property Gmbh	Azabicyles substitués et leur utilisation
WO2013144191A1 (fr)	2012-03-29	2013-10-03	Bayer Intellectual Property Gmbh	2-amino-3-cyanopyridines substituées utilisées comme inhibiteurs de l'échange sodium-calcium et leurs utilisations dans le cas de maladies cardiovasculaires
CA2879369C (fr)	2012-07-20	2020-09-22	Bayer Pharma Aktiengesellschaft	Nouveaux acides 5-aminotetrahydrochinolino-2-carboxyliques et leur utilisation
JP6324956B2 (ja)	2012-07-20	2018-05-16	バイエル・ファルマ・アクティエンゲゼルシャフト	置換アミノインダン−およびアミノテトラリンカルボン酸ならびにその使用
BR112015012571B1 (pt)	2012-11-30	2022-05-24	Astellas Pharma Inc	Compostos de imidazopiridina e usos terapêuticos dos mesmos
WO2014128109A1 (fr)	2013-02-21	2014-08-28	Bayer Pharma Aktiengesellschaft	Formes du {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}méthylcarbamate de méthyle
EP2961755B1 (fr)	2013-03-01	2017-10-18	Bayer Pharma Aktiengesellschaft	Pyrimidines annelées à subsitution trifluorométhyle et utilisation correspondante
HK1222852A1 (zh)	2013-06-21	2017-07-14	Bayer Pharma Aktiengesellschaft	二氨基杂芳基取代的吡唑
CA2917682A1 (fr)	2013-07-10	2015-01-15	Bayer Pharma Aktiengesellschaft	Benzyl-1h-pyrazolo[3,4-b]pyridine et utilisation de cette derniere
WO2015011086A1 (fr)	2013-07-25	2015-01-29	Bayer Pharma Aktiengesellschaft	Stimulateurs de sgc ou activateurs de sgc et inhibiteurs de pde5 en combinaison avec un autre traitement pour la thérapie de la fibrose kystique
US20160221965A1 (en)	2013-09-16	2016-08-04	Bayer Pharma Aktiengesellschaft	Disubstituted trifluoromethyl pyrimidinones and their use
JP2016532721A (ja)	2013-10-07	2016-10-20	バイエルファーマアクチエンゲゼルシャフト	環状チエノウラシルカルボキサミドおよびその使用
US9783552B2 (en)	2013-12-11	2017-10-10	Merck Sharp & Dohme Corp.	Soluble guanylate cyclase activators
WO2015088885A1 (fr)	2013-12-11	2015-06-18	Merck Sharp & Dohme Corp.	Activateurs solubles de guanylate cyclase
EP3094327A1 (fr)	2014-01-13	2016-11-23	Ironwood Pharmaceuticals, Inc.	Utilisation de stimulateurs de la sgc pour le traitement de troubles neuromusculaires
CA2944614A1 (fr)	2014-04-03	2015-10-08	Bayer Pharma Aktiengesellschaft	Acides cyclopentanecarboxyliques a disubstitution 2,5 pour traiter des maladies des voies respiratoires
WO2015150363A1 (fr)	2014-04-03	2015-10-08	Bayer Pharma Aktiengesellschaft	Acides cyclopentanecarboxyliques à disubstitution 2,5 et leur utilisation
EP3126340A2 (fr)	2014-04-03	2017-02-08	Bayer Pharma Aktiengesellschaft	Dérivés chiraux d'acide cyclopentanecarboxylique à disubstitution 2,5 et leur utilisation
US9796733B2 (en)	2014-06-04	2017-10-24	Merck Sharp & Dohme Corp.	Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
CN107074773A (zh)	2014-09-09	2017-08-18	拜耳制药股份公司	取代的n,2‑二芳基喹啉‑4‑甲酰胺及其用途
ES2712886T3 (es)	2014-09-24	2019-05-16	Bayer Pharma AG	Derivados de piridobenzazepina y piridobenzazocina que inhiben el factor XIa
EP3215498B1 (fr)	2014-11-03	2018-08-22	Bayer Pharma Aktiengesellschaft	Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées
TW201625635A (zh)	2014-11-21	2016-07-16	默沙東藥廠	作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
WO2016113205A1 (fr)	2015-01-13	2016-07-21	Bayer Pharma Aktiengesellschaft	Pentafluoréthylpyrimidinones substituées et leur utilisation
UY36586A (es)	2015-03-26	2016-10-31	Bayer Pharma AG	Heterociclilmetiltienouracilos y uso de los mismos
HK1243645A1 (zh)	2015-05-06	2018-07-20	Bayer Pharma Aktiengesellschaft	单独和与pde5抑制剂组合的sgc刺激剂、sgc活化剂用於治疗伴随系统性硬化症(ssc)的指溃疡(du)的用途
US10245264B2 (en)	2015-05-27	2019-04-02	Merck Sharp & Dohme Corp.	Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators
US10213429B2 (en)	2015-05-28	2019-02-26	Merck Sharp & Dohme Corp.	Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
LT3325013T (lt)	2015-07-23	2020-11-10	Bayer Pharma Aktiengesellschaft	Tirpios guanilatciklazės (sgc) stimuliatoriai/aktyvatoriai derinyje su nep inhibitoriumi ir (arba) angiotenzino aii antagonistu ir jų naudojimas
WO2017097671A1 (fr)	2015-12-10	2017-06-15	Bayer Pharma Aktiengesellschaft	Dérivés de perhydropyrrolo[3,4-c]pyrrole substitués et leur utilisation
EP3386979B1 (fr)	2015-12-10	2020-07-29	Bayer Pharma Aktiengesellschaft	Dérivés 2-phényl-3-(pipérazinométhyl)imidazo[1,2-a]pyridine en tant que bloquers de canaux task-1 et task-2 pour le traitement de troubles respiratoires du sommeil
EA201891416A1 (ru)	2015-12-14	2018-12-28	Айронвуд Фармасьютикалз, Инк.	ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ ДИСФУНКЦИИ ЖЕЛУДОЧНО-КИШЕЧНОГО СФИНКТЕРА
CN105461715B (zh) *	2015-12-15	2017-03-29	郑州大明药物科技有限公司	一种利奥西呱中间体的合成方法
WO2017107052A1 (fr)	2015-12-22	2017-06-29	Merck Sharp & Dohme Corp.	Activateurs solubles de guanylate cyclase
WO2017121692A1 (fr)	2016-01-15	2017-07-20	Bayer Pharma Aktiengesellschaft	Sulfamides substitués et leur utilisation
AU2017216429B2 (en) *	2016-02-01	2022-10-06	Cyclerion Therapeutics, Inc.	Use of sGC stimulators for the treatment of Nonalcoholic Steatohepatitis (NASH)
WO2017153235A1 (fr)	2016-03-09	2017-09-14	Bayer Pharma Aktiengesellschaft	N-cyclo-3-aryl-1-naphthamides substitués et leur utilisation
WO2017153231A1 (fr)	2016-03-09	2017-09-14	Bayer Pharma Aktiengesellschaft	N-cyclo-2-arylisochinolinon-4-carboxamides substitués et leur utilisation
WO2017153234A1 (fr)	2016-03-09	2017-09-14	Bayer Pharma Aktiengesellschaft	N-cyclo-2-arylchinolin-4-carboxamides substitués et leur utilisation
US20190119251A1 (en)	2016-05-03	2019-04-25	Bayer Pharma Aktiengesellschaft	Amide-substituted aryltriazole derivatives and uses thereof
AR108263A1 (es)	2016-05-03	2018-08-01	Bayer Pharma AG	Procedimiento para la preparación de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo
US10525041B2 (en)	2016-05-03	2020-01-07	Bayer Pharma Aktiengesellschaft	Fluoroalkyl-substituted aryltriazole derivatives and uses thereof
WO2017191117A1 (fr)	2016-05-03	2017-11-09	Bayer Pharma Aktiengesellschaft	Antagonistes du récepteur v1a destinés à une utilisation dans le traitement de maladies rénales
US10526314B2 (en)	2016-05-03	2020-01-07	Bayer Aktiengesellschaft	Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof
US9988367B2 (en)	2016-05-03	2018-06-05	Bayer Pharma Aktiengesellschaft	Amide-substituted pyridinyltriazole derivatives and uses thereof
CA3022755A1 (fr)	2016-05-03	2017-11-09	Carsten Schmeck	Derives de phenyltriazole a substitution oxoalkyle et utilisations associees
JOP20170113B1 (ar)	2016-05-09	2023-03-28	Bayer Pharma AG	مركبات 5، 6، 7، 8-رباعي هيدرو [1، 2، 4] تريازولو [4، 3-أ] بيريدين 3(2h)-ون مستبدلة ومركبات 2، 5، 6، 7-رباعي هيدرو-3h-بيرولو [2، 1-ج] [1، 2، 4] تريازول-3-ون واستخداماتها
WO2017197555A1 (fr)	2016-05-16	2017-11-23	Merck Sharp & Dohme Corp.	Dérivés de pyrazine fusionnés utiles en tant que stimulateurs de la guanylate cyclase soluble
EP3458063A4 (fr)	2016-05-18	2020-02-26	Merck Sharp & Dohme Corp.	Procédés d'utilisation d'activateurs de la guanylate cyclase soluble dans la triazolo-pyrazinyle pour des troubles fibrotiques
CN109689654A (zh)	2016-07-11	2019-04-26	拜耳医药股份有限公司	7-取代的1-吡啶基-萘啶-3-甲酰胺类及其用途
JOP20190005A1 (ar)	2016-07-20	2019-01-20	Bayer Ag	مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها
WO2018041771A1 (fr)	2016-09-02	2018-03-08	Bayer Pharma Aktiengesellschaft	Thiéno-uraciles substitués par un groupe (1-méthylcyclopropyl)méthyle et leur utilisation
JOP20190045A1 (ar)	2016-09-14	2019-03-14	Bayer Ag	مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.
EP3296298A1 (fr)	2016-09-14	2018-03-21	Bayer Pharma Aktiengesellschaft	1-aryl-naphtyridin-3-ylcarboxamides substitués en position 7 et leur utilisation
MX2019003351A (es)	2016-09-23	2019-08-05	Bayer Ag	Tienouracilos n3-ciclicamente sustituidos y uso de los mismos.
WO2018069148A1 (fr)	2016-10-11	2018-04-19	Bayer Pharma Aktiengesellschaft	Combinaison contenant des activateurs gcs et des antagonistes du récepteur des minéralocorticoïdes
WO2018069126A1 (fr) *	2016-10-11	2018-04-19	Bayer Pharma Aktiengesellschaft	Combinaison contenant des stimulateurs gcs et des antagonistes du récepteur des minéralocorticoïdes
JOP20190080A1 (ar)	2016-10-14	2019-04-11	Bayer Pharma AG	مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
WO2018073144A1 (fr)	2016-10-20	2018-04-26	Bayer Pharma Aktiengesellschaft	Dérivés de triazole substitués par hydroxyalkyle et utilisations associées
WO2018111795A2 (fr)	2016-12-13	2018-06-21	Ironwood Pharmaceuticals, Inc.	Utilisation de stimulateurs de sgc pour le traitement de la motilité œsophagienne
JOP20190141A1 (ar)	2016-12-21	2019-06-12	Bayer Pharma AG	أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي
JOP20190148A1 (ar)	2016-12-21	2019-06-18	Bayer Pharma AG	أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية
EP3338764A1 (fr)	2016-12-21	2018-06-27	Bayer Pharma Aktiengesellschaft	Formes pharmaceutiques comprenant des inhibiteurs de canaux de task-1 et task-3 et leur utilisation pour le traitement des troubles respiratoires
EP3338803A1 (fr)	2016-12-21	2018-06-27	Bayer Pharma Aktiengesellschaft	Formes pharmaceutiques comprenant des inhibiteurs de canaux de task-1 et task-3 et leur utilisation pour le traitement des troubles respiratoires
WO2018153899A1 (fr) *	2017-02-22	2018-08-30	Bayer Pharma Aktiengesellschaft	Agonistes partiels sélectifs du récepteur a1 de l'adénosine en combinaison avec des stimulateurs et/ou activateurs de la guanylate cyclase soluble (sgc)
AU2018251758B2 (en)	2017-04-10	2021-11-18	Bayer Aktiengesellschaft	Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof
TWI770157B (zh)	2017-04-10	2022-07-11	德商拜耳廠股份有限公司	經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途
CA3056501A1 (fr)	2017-04-11	2018-10-18	Sunshine Lake Pharma Co., Ltd.	Composes indazole substitues par fluor et leurs utilisations
CN108690016B (zh) *	2017-04-11	2022-08-12	广东东阳光药业有限公司	吡唑并吡啶类化合物及其用途
WO2018227427A1 (fr)	2017-06-14	2018-12-20	Bayer Aktiengesellschaft	Dérivés de diazépane pontés substitués et leur utilisation
JOP20190284A1 (ar)	2017-06-14	2019-12-11	Bayer Pharma AG	مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس
EP3700898A1 (fr)	2017-10-24	2020-09-02	Bayer Pharma Aktiengesellschaft	Dérivés de triazole substitués et utilisations associées
CA3079770A1 (fr)	2017-10-24	2019-05-02	Bayer Pharma Aktiengesellschaft	Derives de triazole substitues par une amine et utilisations associees
CU20200041A7 (es) *	2017-10-24	2021-03-11	Bayer Ag	Amidas de imidazopiridina sustituidas
EP3700897A1 (fr)	2017-10-24	2020-09-02	Bayer Pharma Aktiengesellschaft	Dérivés de triazole substitués et utilisations associées
CA3084308A1 (fr)	2017-10-24	2019-05-02	Bayer Aktiengesellschaft	Derives de triazole substitues et utilisations associees
WO2019081306A1 (fr)	2017-10-24	2019-05-02	Bayer Pharma Aktiengesellschaft	Dérivés de triazole substitués et utilisations associées
WO2019081291A1 (fr)	2017-10-24	2019-05-02	Bayer Aktiengesellschaft	Promédicaments de dérivés de triazole substitués, et utilisations de ceux-ci
MA50438B1 (fr)	2017-10-24	2022-03-31	Bayer Pharma AG	Promédicaments de dérivés de triazole substitués, et utilisations de ceux-ci
WO2019091847A1 (fr)	2017-11-07	2019-05-16	Bayer Aktiengesellschaft	2,4-dihydro-3h-1,2,4-triazol-3-ones substituées et leur utilisation
JP2021504396A (ja)	2017-12-01	2021-02-15	バイエルファーマアクチエンゲゼルシャフト	（３ｓ）−３−（４−クロロ−３−｛［（２ｓ，３ｒ）−２−（４−クロロフェニル）−４，４，４−トリフルオロ−３−メチルブタノイル］アミノ｝フェニル）−３−シクロ−プロピルプロパン酸を製造する方法及び医薬成分として使用するためのその結晶質形態
US11897887B2 (en) *	2017-12-19	2024-02-13	Tisento Therapeutics Inc.	sGC stimulators
EP3553081A1 (fr)	2018-04-12	2019-10-16	Bayer Aktiengesellschaft	Anticorps greffés de peptide natriurétique auriculaire
EP3553079A1 (fr)	2018-04-12	2019-10-16	Bayer Aktiengesellschaft	Anticorps greffés de peptide natriurétique de type c
EP3553082A1 (fr)	2018-04-12	2019-10-16	Bayer Aktiengesellschaft	Anticorps greffés de peptide natriurétique du cerveau
CN112055584A (zh) *	2018-04-30	2020-12-08	拜耳公司	sGC活化剂和sGC刺激剂用于治疗认知障碍的用途
EP3566704A1 (fr)	2018-05-11	2019-11-13	Bayer Aktiengesellschaft	Utilisation d'antagonistes des récepteurs minéralocorticoïdes non stéroïdiens seuls ou en combinaison, pour le traitement de maladies musculaires ou neuromusculaires
MA52616A (fr)	2018-05-15	2021-03-24	Bayer Ag	Benzamides à substitution 1,3-thiazol-2-yl pour le traitement de maladies associées à la sensibilisation de fibres nerveuses
JOP20200294A1 (ar)	2018-05-17	2020-11-17	Bayer Ag	مشتقات ثنائي هيدروبيرازولو بيرازين كربوكساميد تحمل بدائل
EP3574905A1 (fr)	2018-05-30	2019-12-04	Adverio Pharma GmbH	Procédé d'identification d'un sous-groupe de patients souffrant de dcssc qui bénéficie d'un traitement comportant des stimulateurs sgc et des activateurs sgc à un degré supérieur à celui d'un groupe de contrôle
JP7542518B2 (ja)	2018-07-11	2024-08-30	ティセントセラピューティクスインコーポレーテッド	ミトコンドリア（ｍｉｔｏｃｈｏｎｒｉａｌ）障害の処置のためのｓＧＣ刺激剤の使用
WO2020020789A1 (fr)	2018-07-24	2020-01-30	Bayer Aktiengesellschaft	Formes galéniques pharmaceutiques à libération modifiée à administrer par voie orale
EP3826619A1 (fr)	2018-07-24	2021-06-02	Bayer Aktiengesellschaft	Formes galéniques pharmaceutiques à libération modifiée à administrer par voie orale
US10905667B2 (en)	2018-07-24	2021-02-02	Bayer Pharma Aktiengesellschaft	Orally administrable modified-release pharmaceutical dosage form
US20210393624A1 (en)	2018-11-27	2021-12-23	Bayer Aktiengesellschaft	Process for producing pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
TWI830835B (zh)	2018-12-17	2024-02-01	德商亞德維瑞醫藥有限公司	具改善性質之{4,6-二胺基-2-[5-氟-1-(2-氟芐基)-1H-吡唑並[3,4-b]吡啶-3-基]嘧啶-5-基}胺基甲酸甲酯活性化合物產物、其製造及調配物
WO2020164008A1 (fr)	2019-02-13	2020-08-20	Bayer Aktiengesellschaft	Procédé de préparation de microparticules poreuses
WO2020216669A1 (fr)	2019-04-23	2020-10-29	Bayer Aktiengesellschaft	Imidazopyridinamides substitués par un phényle et leur utilisation
PH12021552817A1 (en)	2019-05-07	2022-09-28	Bayer Ag	Masp inhibitory compounds and uses thereof
WO2020245342A1 (fr)	2019-06-07	2020-12-10	Bayer Aktiengesellschaft	Utilisation d'activateurs de sgc pour le traitement de maladies ophtalmologiques
GEP20247644B (en)	2019-11-06	2024-07-10	Bayer Ag	Inhibitors of adrenoreceptor adrac2
WO2021094208A1 (fr)	2019-11-12	2021-05-20	Bayer Aktiengesellschaft	Antagonistes d'imidazo pyrimidine ep3 substitués
WO2021094209A1 (fr)	2019-11-12	2021-05-20	Bayer Aktiengesellschaft	Dérivés de pyrrolo triazine carboxamide substitués en tant qu'antagonistes du récepteur de la prostaglandine ep3
WO2021094210A1 (fr)	2019-11-12	2021-05-20	Bayer Aktiengesellschaft	Dérivés de pyrazine carboxamide substitués utilisés en tant qu'antagonistes du récepteur de la prostaglandine ep3
EP3822268A1 (fr)	2019-11-15	2021-05-19	Bayer Aktiengesellschaft	Hydantoinamides substitués comme antagonistes d'adamts7
EP3822265A1 (fr)	2019-11-15	2021-05-19	Bayer AG	Hydantoïnamides substitués comme antagonistes d'adamts7
US20230067593A1 (en) *	2020-02-03	2023-03-02	Adverio Pharma Gmbh	Nanoformulations of methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3 -yl]pyrimidin-5-yl} carbamate
WO2021167458A1 (fr)	2020-02-21	2021-08-26	Universiteit Maastricht	Utilisation d'un stimulateur de guanylate cyclase soluble (sgc) ou d'une combinaison d'un stimulateur de sgc et d'un activateur de sgc dans des conditions dans lesquelles le groupe hème de sgc est oxydé ou sgc est déficient en hème
US20230083417A1 (en)	2020-02-26	2023-03-16	Universiteit Maastricht	Therapeutic combination for the treatment of brain ischemia and said therapeutic combination for use in the treatment of brain ischemia
US20230130739A1 (en)	2020-03-26	2023-04-27	Cyclerion Therapeutics, Inc.	DEUTERATED sGC STIMULATORS
EP3925953A1 (fr)	2020-06-16	2021-12-22	Adverio Pharma GmbH	Procédé de préparation de méthyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
WO2022096394A1 (fr)	2020-11-04	2022-05-12	Bayer Aktiengesellschaft	Composés inhibiteurs de masp et leurs utilisations
EP4011904A1 (fr)	2020-12-14	2022-06-15	Bayer Aktiengesellschaft	Composés inhibiteurs de masp et leurs utilisations
WO2022112213A1 (fr)	2020-11-30	2022-06-02	Bayer Aktiengesellschaft	Formes cristallines de 3-[[3-(4-chlorophényl)-5-oxo-4-((2s)-3,3,3-trifluoro-2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]méthyl]-1-[3- (trifluorométhyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide
AU2021398486A1 (en)	2020-12-10	2023-06-22	Bayer Aktiengesellschaft	The use of sgc activators for the treatment of ophthalmologic diseases
EP4011874A1 (fr)	2020-12-10	2022-06-15	Bayer Aktiengesellschaft	Acides carboxyliques de pyrazolo pipéridine substitués
CA3204495A1 (fr)	2020-12-10	2022-06-16	Bayer Aktiengesellschaft	Acides pyrazolo piperidine carboxyliques substitues
US20240109864A1 (en)	2020-12-10	2024-04-04	Bayer Aktiengesellschaft	Substituted pyrazolyl piperidine carboxylic acids
EP4011873A1 (fr)	2020-12-10	2022-06-15	Bayer Aktiengesellschaft	Acides carboxyliques de pyrazolo pipéridine substitués
TW202308634A (zh)	2021-04-20	2023-03-01	美商賽克瑞恩醫療公司	使用sGC刺激劑之CNS疾病治療
EP4326722A1 (fr)	2021-04-20	2024-02-28	Tisento Therapeutics Inc.	Stimulateurs de sgc
EP4396185A1 (fr)	2021-08-31	2024-07-10	Teva Pharmaceuticals International GmbH	Formes solides de vericiguat et leur procédé de préparation
TW202342012A (zh)	2021-12-29	2023-11-01	德商拜耳廠股份有限公司	製備用作醫藥活性化合物的（５ｓ）－｛［２－（４－羧基苯基）乙基］［２－（２－｛［３－氯－４＇－（三氟甲基）聯苯－４－基］甲氧基｝苯基）乙基］胺基｝－５，６，７，８－四氫喹啉－２－羧酸及其結晶形式之方法
TW202342035A (zh)	2021-12-29	2023-11-01	德商拜耳廠股份有限公司	醫藥乾粉吸入配製物
TW202342034A (zh)	2021-12-29	2023-11-01	德商拜耳廠股份有限公司	心肺病症之治療
ES2956054B2 (es)	2022-05-03	2024-07-01	Moehs Iberica Sl	2-(5-FLUORO-1-(2-FLUOROBENCIL)-1H-PIRAZOLO[3,4-b]PIRIDIN-3-IL)-5-NITROSOPIRIMIDIN-4,6-DIAMINA O UNA SAL DE LA MISMA, PROCEDIMIENTO PARA SU PREPARACION Y SU USO EN LA SINTESIS DE VERICIGUAT
CN119300815A (zh)	2022-06-09	2025-01-10	拜耳公司	用于治疗女性射血分数保留型心力衰竭的可溶性鸟苷酸环化酶激活剂
JP2025536343A (ja)	2022-10-18	2025-11-05	ティセントセラピューティクスインコーポレーテッド	ピリミジンｓｇｃ刺激剤
EP4605080A1 (fr)	2022-10-18	2025-08-27	Tisento Therapeutics Inc.	Traitement de maladies mitochondriales avec stimulateurs de sgc
CN116239609A (zh) *	2022-12-06	2023-06-09	山东百诺医药股份有限公司	一种维立西呱的关键杂质及其制备方法
AR133983A1 (es)	2023-09-28	2025-11-19	Bayer Ag	Carboxamidas heterocíclicas sustituidas y su uso
WO2025114276A1 (fr)	2023-12-01	2025-06-05	Krka, D.D., Novo Mesto	Composition orale solide comprenant du vericiguat
US20250205235A1 (en)	2023-12-20	2025-06-26	Adverio Pharma Gmbh	Dose regimen for vericiguat
CN117924280B (zh) *	2024-03-20	2024-07-12	中国人民解放军军事科学院军事医学研究院	取代噻吩基-5-氟-1h-吡唑并吡啶类化合物及其用途

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH01198481A (ja) *	1988-02-01	1989-08-10	Canon Inc	マイクロ波プラズマｃｖｄ法による堆積膜形成法
GB9013750D0 (en)	1990-06-20	1990-08-08	Pfizer Ltd	Therapeutic agents
EP0463754A1 (fr)	1990-06-25	1992-01-02	Rohm And Haas Company	Stabilisation de polymères de glutarimide
DK181190D0 (da)	1990-07-30	1990-07-30	Lundbeck & Co As H	3-aryl-indol- eller 3-aryl-indazolderivater
GB9301192D0 (en)	1993-06-09	1993-06-09	Trott Francis W	Flower shaped mechanised table
GB9314412D0 (en)	1993-07-13	1993-08-25	Rhone Poulenc Agriculture	New compositions of matter
GB9401090D0 (en)	1994-01-21	1994-03-16	Glaxo Lab Sa	Chemical compounds
DE19642255A1 (de) *	1996-10-14	1998-04-16	Bayer Ag	Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
JP4351298B2 (ja)	1996-10-14	2009-10-28	バイエル・アクチエンゲゼルシヤフト	新規へテロシクリルメチル置換ピラゾール誘導体
US6008243A (en)	1996-10-24	1999-12-28	Agouron Pharmaceuticals, Inc.	Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
FR2757157B1 (fr)	1996-12-13	1999-12-31	Sanofi Sa	Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
HRP20020585B1 (hr)	1997-11-12	2013-02-28	Bayer Schering Pharma Aktiengesellschaft	2-fenil supstituirani imidazotriazinoni kao inhibitori fosfodiesteraze
US6451805B1 (en)	1997-11-14	2002-09-17	Bayer Aktiengesellschaft	Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
DE19834044A1 (de)	1998-07-29	2000-02-03	Bayer Ag	Neue substituierte Pyrazolderivate
DE19834047A1 (de)	1998-07-29	2000-02-03	Bayer Ag	Substituierte Pyrazolderivate
DE19834045A1 (de)	1998-07-29	2000-02-03	Bayer Ag	(4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19846514A1 (de)	1998-10-09	2000-04-20	Bayer Ag	Neue Heterocyclyl-methyl-substituierte Pyrazole
GB0002666D0 (en)	2000-02-04	2000-03-29	Univ London	Blockade of voltage dependent sodium channels
AR031176A1 (es)	2000-11-22	2003-09-10	Bayer Ag	Nuevos derivados de pirazolpiridina sustituidos con piridina
CA2429308C (fr)	2000-11-22	2010-09-21	Bayer Aktiengesellschaft	Nouveaux derives de pyrazolopyridine substitues par lactame
DE10057751A1 (de)	2000-11-22	2002-05-23	Bayer Ag	Neue Carbamat-substituierte Pyrazolopyridinderivate
DE10057754A1 (de)	2000-11-22	2002-05-23	Bayer Ag	Neue Sulfonamid-substituierte Pyrazolopyridinderivate
NZ526871A (en)	2001-01-25	2006-01-27	Bristol Myers Squibb Co	Pharmaceutical dosage forms of epothilones for oral administration
DE10122894A1 (de)	2001-05-11	2002-11-14	Bayer Ag	Neue Sulfonat-substituierte Pyrazolopyridinderivate
DE10132416A1 (de)	2001-07-04	2003-01-16	Bayer Ag	Neue Morpholin-überbrückte Pyrazolopyridinderivate
WO2003035005A2 (fr)	2001-10-26	2003-05-01	University Of Connecticut	Heteroindanes: nouvelle classe de ligands cannabimimetiques efficaces
US7790905B2 (en)	2002-02-15	2010-09-07	Mcneil-Ppc, Inc.	Pharmaceutical propylene glycol solvate compositions
WO2003076408A2 (fr)	2002-03-08	2003-09-18	Abbott Laboratories	Derives d'indazole qui sont des activateurs de guanylate cyclase soluble
GR1004350B (el) *	2002-03-29	2003-09-26		Συσκευη εισπνοων ξηρης σκονης
DE10220570A1 (de) *	2002-05-08	2003-11-20	Bayer Ag	Carbamat-substituierte Pyrazolopyridine
DE10222550A1 (de)	2002-05-17	2003-11-27	Bayer Ag	Substituierte Benzyl-pyrazolopyridine
DE10232571A1 (de)	2002-07-18	2004-02-05	Bayer Ag	4-Aminosubstituierte Pyrimidinderivate
DE10232572A1 (de)	2002-07-18	2004-02-05	Bayer Ag	Neue 2,5-disubstituierte Pyrimidinderivate
DE10242941A1 (de)	2002-09-16	2004-03-18	Bayer Ag	Substituiertes Pyrazolderivat
DE10244810A1 (de)	2002-09-26	2004-04-08	Bayer Ag	Neue Morpholin-überbrückte Indazolderivate
BRPI0306214B1 (pt)	2002-11-20	2017-08-08	Japan Tobacco Inc.	4-oxoquinoline compound and use of this as a hiv integrase inhibitor
ATE480520T1 (de)	2003-05-09	2010-09-15	Asahi Glass Co Ltd	Verfahren zur herstellung von 3-substituiertem 2- chlor-5-fluorpyridin bzw. einem salz davon
JP4499721B2 (ja)	2003-06-30	2010-07-07	ヒフバイオ，インク．	化合物、組成物および方法
PE20050483A1 (es)	2003-10-31	2005-08-25	Arena Pharm Inc	Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
CN100355732C (zh)	2003-11-03	2007-12-19	上海药明康德新药开发有限公司	2－氯－5－氟－烟酸酯及酸的制备方法
DE10351903A1 (de)	2003-11-06	2005-06-09	Bayer Healthcare Ag	Neue Kombination
GB0403819D0 (en)	2004-02-20	2004-03-24	Merck Sharp & Dohme	New compounds
US7514463B2 (en)	2004-08-20	2009-04-07	University Of Kansas	Lonidamine analogues and their use in male contraception and cancer treatment
JP2008515825A (ja)	2004-10-05	2008-05-15	バイエル・ヘルスケア・アクチェンゲゼルシャフト	気管支収縮および肺血管収縮の処置用のグアニル酸シクラーゼ刺激因子および一酸化窒素
DE102005047945A1 (de)	2005-07-16	2007-01-18	Bayer Healthcare Ag	Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Raynaud Phänomenen
BRPI0614001A2 (pt)	2005-07-18	2011-03-01	Bayer Healthcare Ag	uso de ativadores e estimuladores de guanilato ciclase solúvel para a prevenção ou tratamento de distúrbios renais
DE102006021733A1 (de)	2006-05-09	2007-11-22	Bayer Healthcare Ag	3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung
DE102006043443A1 (de)	2006-09-15	2008-03-27	Bayer Healthcare Ag	Neue aza-bicyclische Verbindungen und ihre Verwendung
EP2170884A2 (fr)	2007-06-25	2010-04-07	Boehringer Ingelheim International GmbH	Composés chimiques
JP5553751B2 (ja)	2007-07-31	2014-07-16	バーテックスファーマシューティカルズインコーポレイテッド	５−フルオロ−１Ｈ−ピラゾロ［３，４−ｂ］ピリジン−３−アミンおよびその誘導体を調製するためのプロセス
JP2011513483A (ja)	2008-03-10	2011-04-28	バーテックスファーマシューティカルズインコーポレイテッド	タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン
DE102008063992A1 (de) *	2008-12-19	2010-09-02	Lerner, Zinoviy, Dipl.-Ing.	Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
DE102009004245A1 (de)	2009-01-09	2010-07-15	Bayer Schering Pharma Aktiengesellschaft	Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung
AR077898A1 (es)	2009-08-26	2011-09-28	Nycomed Gmbh	Metilpirrolopirimidincarboxamidas
DK3415515T3 (da)	2009-11-27	2020-03-16	Adverio Pharma Gmbh	Fremgangsmåde til fremstilling af methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamat
UY33040A (es)	2009-11-27	2011-06-30	Bayer Schering Pahrma Akitengesellschaft	Nuevas formas polimorfas de {4,6diamino-2-[1-(2-fluorobencil-1h-pirazol[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo
UY33041A (es)	2009-11-27	2011-06-30	Bayer Schering Pharma Aktienegesellschaft	Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
JP5960061B2 (ja)	2009-12-18	2016-08-02	エクソドスライフサイエンシーズリミテッドパートナーシップ	末梢血管疾患を治療するための方法および組成物
WO2011115804A1 (fr)	2010-03-17	2011-09-22	Ironwood Pharmaceuticals, Inc.	Stimulateurs de sgc
MX2012013574A (es) *	2010-05-26	2013-01-24	Bayer Ip Gmbh	El uso de estimuladores de la sgc, activadores de la sgc, solos y en combinacion con inhibidores de la pde5 para el tratamiento de esclerosis sistemica (ecs).
DE102010021637A1 (de)	2010-05-26	2011-12-01	Bayer Schering Pharma Aktiengesellschaft	Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
CA2800541C (fr)	2010-05-27	2016-03-22	Merck Sharp & Dohme Corp.	Activateurs de guanylate cyclase soluble
PE20130779A1 (es)	2010-07-09	2013-06-21	Bayer Ip Gmbh	Pirimidinas y triazinas condensadas y su uso
DE102010040233A1 (de)	2010-09-03	2012-03-08	Bayer Schering Pharma Aktiengesellschaft	Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010040234A1 (de)	2010-09-03	2012-03-08	Bayer Schering Pharma Aktiengesellschaft	Verfahren zur Herstellung von 5-Flour-1H-pyrazolo[3,4-b]pyridin-3-carbonitril
DE102010043379A1 (de)	2010-11-04	2012-05-10	Bayer Schering Pharma Aktiengesellschaft	Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
DE102010043380A1 (de)	2010-11-04	2012-05-10	Bayer Schering Pharma Aktiengesellschaft	Benzyl-substituierte Carbamate und ihre Verwendung
CA2835220A1 (fr)	2011-05-31	2012-12-06	Theravance, Inc.	Inhibiteurs de neprilysine
WO2013030288A1 (fr)	2011-09-02	2013-03-07	Bayer Intellectual Property Gmbh	Pyrimidines annelées substituées et leur utilisation
PE20190180A1 (es)	2011-11-25	2019-02-01	Adverio Pharma Gmbh	Procedimiento de preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas
DE102012200352A1 (de)	2012-01-11	2013-07-11	Bayer Intellectual Property Gmbh	Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung

2010
- 2010-05-26 DE DE102010021637A patent/DE102010021637A1/de not_active Withdrawn
2011
- 2011-05-19 US US13/111,856 patent/US8420656B2/en active Active
- 2011-05-19 UY UY0001033396A patent/UY33396A/es active IP Right Grant
- 2011-05-24 ME MEP-2016-64A patent/ME02393B/fr unknown
- 2011-05-24 SG SG2012082152A patent/SG185460A1/en unknown
- 2011-05-24 MY MYPI2012700999A patent/MY164356A/en unknown
- 2011-05-24 PL PL11720806T patent/PL2576547T3/pl unknown
- 2011-05-24 CU CU2012000161A patent/CU24086B1/es active IP Right Grant
- 2011-05-24 NZ NZ603800A patent/NZ603800A/en unknown
- 2011-05-24 MX MX2012013324A patent/MX2012013324A/es active IP Right Grant
- 2011-05-24 SI SI201130781A patent/SI2576547T1/sl unknown
- 2011-05-24 AR ARP110101777A patent/AR081628A1/es active IP Right Grant
- 2011-05-24 BR BR112012030010-5A patent/BR112012030010A2/pt not_active Application Discontinuation
- 2011-05-24 JO JOP/2011/0171A patent/JO3199B1/ar active
- 2011-05-24 RS RS20160263A patent/RS54704B1/sr unknown
- 2011-05-24 WO PCT/EP2011/058431 patent/WO2011147809A1/fr not_active Ceased
- 2011-05-24 CN CN201180026010.7A patent/CN102939289B/zh active Active
- 2011-05-24 MA MA35391A patent/MA34248B1/fr unknown
- 2011-05-24 CA CA2800697A patent/CA2800697C/fr active Active
- 2011-05-24 PH PH1/2012/502320A patent/PH12012502320A1/en unknown
- 2011-05-24 BR BR122020023470-9A patent/BR122020023470B1/pt active IP Right Grant
- 2011-05-24 EP EP11720806.6A patent/EP2576547B1/fr active Active
- 2011-05-24 ES ES11720806.6T patent/ES2567795T3/es active Active
- 2011-05-24 UA UAA201214902A patent/UA109660C2/uk unknown
- 2011-05-24 EA EA201291336A patent/EA023631B9/ru not_active IP Right Cessation
- 2011-05-24 PE PE2012002172A patent/PE20130402A1/es active IP Right Grant
- 2011-05-24 HR HRP20160370TT patent/HRP20160370T1/hr unknown
- 2011-05-24 JP JP2013511643A patent/JP5896991B2/ja active Active
- 2011-05-24 KR KR1020127033601A patent/KR101862420B1/ko active Active
- 2011-05-24 DK DK11720806.6T patent/DK2576547T3/en active
- 2011-05-24 AU AU2011257335A patent/AU2011257335B2/en active Active
- 2011-05-24 HU HUE11720806A patent/HUE026912T2/en unknown
- 2011-05-25 TW TW100118222A patent/TWI516263B/zh active
2012
- 2012-11-15 IL IL223050A patent/IL223050A/en active IP Right Grant
- 2012-11-16 CO CO12208156A patent/CO6640226A2/es active IP Right Grant
- 2012-11-20 CL CL2012003226A patent/CL2012003226A1/es unknown
- 2012-11-21 GT GT201200313A patent/GT201200313A/es unknown
- 2012-11-23 TN TNP2012000549A patent/TN2012000549A1/en unknown
- 2012-11-23 DO DO2012000299A patent/DOP2012000299A/es unknown
- 2012-11-26 CR CR20120596A patent/CR20120596A/es unknown
- 2012-11-26 EC ECSP12012310 patent/ECSP12012310A/es unknown
2013
- 2013-03-27 US US13/851,373 patent/US8921377B2/en active Active
2014
- 2014-11-24 US US14/552,122 patent/US9266885B2/en active Active
2016
- 2016-01-15 US US14/996,678 patent/US20160129004A1/en not_active Abandoned
- 2016-04-12 CY CY20161100301T patent/CY1117372T1/el unknown
- 2016-11-10 US US15/348,545 patent/US9993476B2/en active Active
- 2016-12-20 IL IL249669A patent/IL249669B/en active IP Right Grant
2018
- 2018-05-16 US US15/981,598 patent/US10736896B2/en active Active
2020
- 2020-07-02 US US16/919,385 patent/US11439642B2/en active Active
2021
- 2021-08-20 CY CY2021021C patent/CY2021021I2/el unknown
- 2021-08-26 LT LTPA2021518C patent/LTC2576547I2/lt unknown
- 2021-08-27 HU HUS2100032C patent/HUS2100032I1/hu unknown
- 2021-08-30 FR FR21C1038C patent/FR21C1038I2/fr active Active
- 2021-09-01 LU LU00221C patent/LUC00221I2/fr unknown
- 2021-09-06 NO NO2021032C patent/NO2021032I1/no unknown
- 2021-12-01 NL NL301146C patent/NL301146I2/nl unknown
2022
- 2022-08-18 US US17/820,667 patent/US12064429B2/en active Active

Also Published As

Publication number	Publication date
BR112012030010A2 (pt)	2020-09-01
PH12012502320A1 (en)	2013-02-11
EP2576547A1 (fr)	2013-04-10
US8420656B2 (en)	2013-04-16
SG185460A1 (en)	2012-12-28
BR122020023470B1 (pt)	2022-07-12
TN2012000549A1 (en)	2014-04-01
CL2012003226A1 (es)	2013-07-26
ME02393B (fr)	2016-09-20
PL2576547T3 (pl)	2016-07-29
US20180263981A1 (en)	2018-09-20
US20160129004A1 (en)	2016-05-12
IL249669A0 (en)	2017-02-28
UA109660C2 (xx)	2015-09-25
HK1182112A1 (zh)	2013-11-22
CR20120596A (es)	2013-04-22
HUS2100032I1 (hu)	2021-09-28
US8921377B2 (en)	2014-12-30
US11439642B2 (en)	2022-09-13
IL249669B (en)	2020-05-31
ECSP12012310A (es)	2012-12-28
LTC2576547I2 (fr)	2022-10-25
EA201291336A1 (ru)	2013-04-30
DOP2012000299A (es)	2013-03-31
US20200397785A1 (en)	2020-12-24
MX2012013324A (es)	2012-12-05
JP5896991B2 (ja)	2016-03-30
NO2021032I1 (no)	2021-09-06
JO3199B1 (ar)	2018-03-08
US20130237551A1 (en)	2013-09-12
PE20130402A1 (es)	2013-04-13
IL223050A0 (en)	2013-02-03
NL301146I2 (nl)	2022-07-06
GT201200313A (es)	2014-01-31
ES2567795T3 (es)	2016-04-26
US20170273977A1 (en)	2017-09-28
TW201210592A (en)	2012-03-16
LUC00221I2 (fr)	2024-10-04
UY33396A (es)	2011-12-30
LTPA2021518I1 (fr)	2021-09-10
IL223050A (en)	2017-01-31
US12064429B2 (en)	2024-08-20
DK2576547T3 (en)	2016-04-25
CY2021021I1 (el)	2021-12-31
US9993476B2 (en)	2018-06-12
MA34248B1 (fr)	2013-05-02
CY1117372T1 (el)	2017-04-26
RS54704B1 (sr)	2016-08-31
CN102939289A (zh)	2013-02-20
US20120022084A1 (en)	2012-01-26
NL301146I1 (nl)	2021-12-08
MY164356A (en)	2017-12-15
CN102939289B (zh)	2016-01-20
KR20130116000A (ko)	2013-10-22
EA023631B1 (ru)	2016-06-30
FR21C1038I1 (fr)	2021-10-15
AU2011257335A1 (en)	2012-12-20
CU20120161A7 (es)	2013-02-26
US20220409618A1 (en)	2022-12-29
NZ603800A (en)	2014-10-31
SI2576547T1 (sl)	2016-05-31
US9266885B2 (en)	2016-02-23
CY2021021I2 (el)	2021-12-31
AR081628A1 (es)	2012-10-10
DE102010021637A1 (de)	2011-12-01
CU24086B1 (es)	2015-03-30
CA2800697A1 (fr)	2011-12-01
TWI516263B (zh)	2016-01-11
HRP20160370T1 (hr)	2016-05-06
HUE026912T2 (en)	2016-07-28
JP2013530150A (ja)	2013-07-25
CO6640226A2 (es)	2013-03-22
KR101862420B1 (ko)	2018-07-04
WO2011147809A1 (fr)	2011-12-01
EA023631B9 (ru)	2017-04-28
US20150080414A1 (en)	2015-03-19
CA2800697C (fr)	2018-08-07
EP2576547B1 (fr)	2016-01-27
US10736896B2 (en)	2020-08-11
AU2011257335B2 (en)	2015-12-03

Publication	Publication Date	Title
FR21C1038I2 (fr)	2022-09-02	5-fluoro-1h-pyrazolopyridines substituees et leur utilisation
FR22C1032I2 (fr)	2023-06-02	Compositions anti-cgrp et leur utilisation
FR24C1035I2 (fr)	2025-05-30	Composés et leur utilisation
EP2739695A4 (fr)	2015-04-01	Adhésifs et leur utilisation
EP2686305A4 (fr)	2014-08-06	Quinazolinediones et leur utilisation
EP2751270A4 (fr)	2015-04-29	Complexes oligomère-conjugué et leur utilisation
EP2563135A4 (fr)	2013-09-25	Composition phytosanitaire et utilisation associée
EP2758183A4 (fr)	2015-09-02	Compositions biodégradables et leur utilisation
HUE037355T2 (hu)	2018-08-28	Nedvszívó szerkezet
EP2543405A4 (fr)	2015-06-17	Seringue
BR112012017441A2 (pt)	2016-04-19	compostos e métodos
DK2613884T3 (da)	2014-08-11	Findelingsindretning
EP2888286A4 (fr)	2016-03-23	Anticorps dirigés contre des haptènes de quétiapine et leur utilisation
EP2626744A4 (fr)	2015-08-26	Liant de toner et toner
HRP20160922T1 (hr)	2016-10-07	Oligopeptidni spojevi i njihove uporabe
EP2686396A4 (fr)	2015-03-11	Composition adhésive et son utilisation
EP2575453A4 (fr)	2015-12-23	Composés oligo-benzamide et leur utilisation
EP2887928A4 (fr)	2016-03-23	Rétinoïdes et leur utilisation
FR2957073B1 (fr)	2012-06-22	Beton ultraleger et son utilisation
EP2808349A4 (fr)	2015-10-14	Copolymère triséquencé et utilisation associée
EP2855506A4 (fr)	2015-12-02	Peptide et utilisation associée
EP2895569A4 (fr)	2016-04-13	Compositions adhésives et leur utilisation
EP2547464A4 (fr)	2015-04-22	Agencement et agencement de ventilation
FR2964937B1 (fr)	2013-07-12	Triporteur et direction de triporteur
FR2989572B1 (fr)	2015-05-01	Sparadrap et son utilisation